Xie Shanzhou, Su Yuting, Zhang Jinyan, Yin Fuqiang, Liu Xia
Key Laboratory of Longevity and Aging-Related Disease of Chinese Ministry of Education, Center for Translational Medicine and School of Basic Medical Sciences, Guangxi Medical University, Nanning, China.
Life Sciences Institute, Guangxi Medical University, Nanning, China.
Transl Cancer Res. 2024 Sep 30;13(9):4800-4812. doi: 10.21037/tcr-24-292. Epub 2024 Sep 27.
Ovarian cancer (OC) is the most malignant gynecologic cancer, and chemoresistance is a major cause of treatment failure in patients with OC. The understanding of microRNA (miRNA) in cancer is limited, and the role of miRNA (miR)-450b-5p in cancer drug resistance is unknown. In this study, we aim to evaluate the role of miR-450b-5p in drug-resistant OC and its underlying mechanisms.
MiR-450b-5p expression was assessed in drug-sensitive and resistant OC cells via quantitative real-time polymerase chain reaction. Cell viability was evaluated using the Cell Counting Kit-8 assay. Progression-free survival (PFS) and overall survival (OS) curves were generated using the Kaplan-Meier method and the log-rank test. Target genes of miR-450b-5p were identified from the Cancer MIRNome database. Co-expressed genes were obtained from The Cancer Genome Atlas and Cancer Genome cBioportal for pathway enrichment and functional clustering analysis.
The miRNA-450b-5p expression was significantly increased in A2780 and SKOV3 OC-resistant cells and significantly increased by 17-fold in the A2780-CBP-Lv-miR-450b-5p cells compared to A2780-CBP and A2780-CBP-Lv-NC cells. The up-regulated expression of miR-450b-5p increased the cell viability and half maximal inhibitory concentration (IC) of A2780 platinum-resistant cells and was associated with poor OS. We obtained 33 potential target genes of miR-450b-5p and beta-actin (ACTB) might be a potential target of miR-450b-5p. Low expression of ACTB predicted poor OS and PFS. We obtained 362 common genes co-expressed with ACTB, which involved 4 critical pathways. PI3K acted as an upstream pathway of the other three pathways, which ultimately responded to drug resistance regulation in OC. The genes enriched in four pathways were cross-analyzed and 13 overlapping genes were obtained. These 13 genes were also significantly and positively co-expressed with ACTB at both protein and mRNA levels.
High expression of miRNA-450b-5p might affect drug resistance and prognosis in OC by targeting 13 co-expressed genes of ACTB directly through the PI3K/Akt signaling pathway. Thus, miR-450b-5p might provide a new therapeutic target for drug resistance in OC.
卵巢癌(OC)是最恶性的妇科癌症,化疗耐药是OC患者治疗失败的主要原因。对癌症中微小RNA(miRNA)的了解有限,miRNA(miR)-450b-5p在癌症耐药中的作用尚不清楚。在本研究中,我们旨在评估miR-450b-5p在耐药性OC中的作用及其潜在机制。
通过定量实时聚合酶链反应评估miR-450b-5p在药物敏感和耐药OC细胞中的表达。使用细胞计数试剂盒-8检测法评估细胞活力。采用Kaplan-Meier法和对数秩检验生成无进展生存期(PFS)和总生存期(OS)曲线。从癌症miRnome数据库中鉴定miR-450b-5p的靶基因。从癌症基因组图谱和癌症基因组cBioportal获得共表达基因,用于通路富集和功能聚类分析。
miR-450b-5p在A2780和SKOV3 OC耐药细胞中的表达显著增加,与A2780-CBP和A2780-CBP-Lv-NC细胞相比,A2780-CBP-Lv-miR-450b-5p细胞中的miR-表达显著增加了17倍。miR-450b-5p表达上调增加了A2780铂耐药细胞的细胞活力和半数最大抑制浓度(IC),并与较差的OS相关。我们获得了miR-450b-5p的33个潜在靶基因,β-肌动蛋白(ACTB)可能是miR-450b-5p的潜在靶标。ACTB低表达预示着较差的OS和PFS。我们获得了与ACTB共表达的362个常见基因,这些基因涉及4条关键通路。PI3K作为其他三条通路的上游通路,最终对OC中的耐药性调节作出反应。对四条通路中富集的基因进行交叉分析,获得了13个重叠基因。这13个基因在蛋白质和mRNA水平上也与ACTB显著正共表达。
miR-450b-5p的高表达可能通过PI3K/Akt信号通路直接靶向ACTB的13个共表达基因,影响OC的耐药性和预后。因此,miR-450b-5p可能为OC耐药提供新的治疗靶点。